Lantern Pharma to Report First Quarter 2026 Financial Results on May 15

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms.

The announcement comes as Lantern continues to advance its pipeline of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.

Beyond its clinical programs, Lantern has made strides in commercializing its AI capabilities. withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. This development could position Lantern as a key player in the AI-driven drug discovery space, potentially transforming how cancer therapies are developed.

Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. The company’s use of artificial intelligence and machine learning, particularly through its proprietary RADR® platform, aims to streamline the development of cancer therapies and reduce the time and cost associated with traditional drug development.

The upcoming financial report will be closely watched by investors and industry observers, as it will provide insight into the company’s financial health and the progress of its clinical trials. The operational updates may also shed light on the adoption of withZeta.ai and its impact on Lantern’s revenue.

For more information, the full press release is available at https://ibn.fm/dVleQ. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lantern Pharma to Report First Quarter 2026 Financial Results on May 15.

The post Lantern Pharma to Report First Quarter 2026 Financial Results on May 15 appeared first on citybuzz.